Please login to the form below

Not currently logged in
Email:
Password:

Merck appoints new North America and China biopharma leaders

Gary Zieziula and Marc Horn take on new roles

Merck Gary ZieziulaGerman pharmaceutical company Merck has made two new appointments to its senior leadership team, promoting Gary Zieziula and Marc Horn.

Zieziula (pictured right) has been appointed president and managing director for Merck's North American biopharma, EMD Serono, replacing Paris Panayiotopoulos with immediate effect.

He will be responsible for the Massachusetts-based biopharma business' strategic direction and growth across the US and Canada. 

Zieziula brings over 30 years of pharmaceutical experience to the role, having held senior management positions at Amag Pharmaceuticals, Bristol Myers-Squibb, MSD and Roche, before joining Merck in 2015 as chief commercial officer for the US.

Meanwhile, Marc Horn will take on the role of managing director for Merck's biopharma business in China from 1 April.

Merck Marc HornBased in Beijing, Horn (pictured left) is currently chief financial officer overseeing Merck's healthcare, life science and performance materials sectors across Eastern Asia.

He has more than 16 years of financial experience in the industry and prior to joining Merck in 2014 as chief financial officer, Horn held management roles at Bayer and Lanxess.

Horn will report to Allan Gabor, Merck's current managing director for China, who has been promoted to president of the Asian-Pacific region for biopharma.

2nd February 2016

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Ashfield

Ashfield, part of UDG Healthcare plc, is a global leader in commercialisation services for the healthcare industry. We partner with...

Latest intelligence

Brain power: fresh approaches to Alzheimer’s drug discovery
New alliances are learning from past mistakes and breaking down research barriers...
Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...
London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...

Infographics